Stockscreener 앱 받기
79.93
0.15%
-0.12
시장 영업 전:
79.53
-0.40
-0.50%
Astrazeneca PLC 주식(AZN)의 최신 뉴스
What institutional flow reveals about AstraZeneca PLC Depositary ReceiptJuly 2025 Market Mood & Pattern Based Trade Signal System - Newser
Technical analysis overview for AstraZeneca PLC Depositary Receipt stockMarket Risk Summary & Weekly High Potential Stock Alerts - Newser
Signal strength of AstraZeneca PLC Depositary Receipt stock in tech scannersWeekly Trade Summary & Reliable Intraday Trade Plans - Newser
What momentum shifts mean for AstraZeneca PLC Depositary ReceiptJuly 2025 Institutional & Growth Focused Entry Reports - Newser
Real time scanner hits for AstraZeneca PLC Depositary Receipt explained2025 Market Sentiment & Risk Managed Trade Strategies - Newser
University of Michigan Suit Targets AstraZeneca FluMist Profits - Bloomberg Law News
AstraZeneca increasing focus on US market, as it is 'first to provide access to patients': CFO [Video] - AOL.com
Global Pharmaceuticals Market to Register Immense Growth at a CAGR of ~7% by 2032 | DelveInsight - GlobeNewswire Inc.
AstraZeneca and Icon Plc’s Study on ATTR Amyloidosis: Key Insights for Investors - TipRanks
Published on: 2025-08-27 08:26:33 - Newser
Va. backs big pharma deals for AstraZeneca in Albemarle, Eli Lilly in Goochland - Richmond Times-Dispatch
Evaluating AstraZeneca PLC Depositary Receipt with trendline analysis2025 Big Picture & Accurate Entry and Exit Point Alerts - Newser
Tools to monitor AstraZeneca PLC Depositary Receipt recovery probabilityWeekly Market Report & Weekly Top Gainers Alerts - Newser
AstraZeneca bounces back from scandal in China - Financial Times
AstraZeneca PLC Depositary Receipt Recovery Hinges on Volume Breakout getLinesFromResByArray error: size == 0 - 더경남뉴스
AstraZeneca Sees Increase in Voting Rights by The Capital Group - TipRanks
What candlestick patterns are forming on AstraZeneca PLC Depositary Receipt2025 Market Outlook & Daily Stock Trend Watchlist - Newser
Published on: 2025-08-26 09:01:55 - Newser
Is a relief rally coming for AstraZeneca PLC Depositary Receipt holdersWeekly Profit Analysis & Reliable Volume Spike Trade Alerts - Newser
Multi asset correlation models including AstraZeneca PLC Depositary Receipt2025 Macro Impact & Breakout Confirmation Trade Signals - Newser
AstraZeneca PLC ADR falls Monday, underperforms market - MarketWatch
AstraZeneca’s New NSCLC Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Daiichi Sankyo and AstraZeneca’s Datroway receives approval in China - Pharmaceutical Technology
Is it time to cut losses on AstraZeneca PLC Depositary ReceiptPrice Action & Stock Market Timing Techniques - Newser
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
AstraZeneca’s New Asthma Study: Potential Market Impact - TipRanks
AstraZeneca’s New Study on Tezepelumab for CRSwNP: A Potential Game-Changer - TipRanks
Amgen and AstraZeneca Launch Promising Phase 3 Lung Cancer Study - TipRanks
AstraZeneca’s Innovative Lung Cancer Screening Study: A Game Changer for Early Detection - TipRanks
AstraZeneca’s ARISE Study: Real-World Insights on Acalabrutinib for CLL - TipRanks
AstraZeneca’s DESTINY-Endometrial01 Study: A New Horizon in Endometrial Cancer Treatment - TipRanks
AstraZeneca’s AZD9829 Study: A New Hope in Hematological Cancer Treatment - TipRanks
AstraZeneca’s GEMINI-PeriOp GC Study: A New Frontier in Gastroesophageal Cancer Treatment - TipRanks
AstraZeneca’s CHRONICLES COPD Study: A New Horizon in COPD Treatment - TipRanks
AstraZeneca’s New CAR T-Cell Therapy Study: A Potential Game-Changer for Multiple Myeloma - TipRanks
AstraZeneca’s New Study on Crohn’s Disease Treatment: Key Insights for Investors - TipRanks
AstraZeneca’s Phase III COPD Study: A Potential Game-Changer in Respiratory Treatment - TipRanks
Earnings call transcript: AstraZeneca’s Q2 2025 earnings exceed expectations - Investing.com
AstraZeneca PLC ADR outperforms market on strong trading day - MarketWatch
AstraZeneca’s Benralizumab Study Completes: A Potential Game-Changer for COPD Treatment - TipRanks
AstraZeneca’s Phase 3 Study on Advanced Biliary Tract Cancer: A Potential Game-Changer? - TipRanks
AstraZeneca’s Atuliflapon Study: A New Hope for Uncontrolled Asthma - TipRanks
AstraZeneca’s Saruparib Study: A New Frontier in Cancer Treatment? - TipRanks
AstraZeneca’s Phase III Study on Endometrial Cancer: A Potential Game Changer? - TipRanks
AstraZeneca advances Wednesday, outperforms market - MarketWatch
AstraZeneca’s New Asthma Treatment Study: What Investors Should Know - TipRanks
Fitch Upgrades AstraZeneca on Profit Growth; Ratings Withdrawn for Commercial Reasons - MarketScreener
AstraZeneca’s Benralizumab Study: A Step Forward in COPD Treatment - TipRanks
Risk adjusted return profile for AstraZeneca PLC Depositary Receipt analyzed2025 Risk Factors & Intraday High Probability Alerts - Newser
AstraZeneca’s Promising Asthma Treatment: A Closer Look at the Atuliflapon Study - TipRanks
AstraZeneca’s Phase I Study on Saruparib: A Potential Game-Changer in Cancer Treatment - TipRanks
AstraZeneca’s New Study on Advanced Biliary Tract Cancer: A Potential Game Changer? - TipRanks
AstraZeneca Receives Chinese Approval to Acquire FibroGen China - MarketScreener
AstraZeneca’s Pediatric Hyperkalaemia Study: A Potential Market Game-Changer - MSN
AstraZeneca CFO Aradhana Sarin sells 9,563 shares in London transaction - Investing.com
AstraZeneca’s New Study on T-DXd Offers Hope for HER2-Positive Tumor Patients - MSN
AstraZeneca (LSE:AZN) Launches FluMist Home For At-Home Influenza Vaccination - Yahoo Finance
AstraZeneca’s LATIFY Study: A New Hope for NSCLC Treatment? - The Globe and Mail
AstraZeneca’s CKD Registry Study: A Strategic Move in Nephrology - MSN
AstraZeneca’s Promising Study on Durvalumab and Olaparib in Advanced Bladder Cancer - MSN
AstraZeneca’s Phase I Study on Balcinrenone/Dapagliflozin: Key Insights for Investors - MSN
Can swing trading help recover from AstraZeneca PLC Depositary Receipt lossesPortfolio Value Summary & AI Enhanced Market Trend Forecasts - Newser
자본화:
|
볼륨(24시간):